Clinical Trial Detail

NCT ID NCT03361228
Title A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Incyte Corporation
Indications

lung non-small cell carcinoma

melanoma

colorectal cancer

Advanced Solid Tumor

transitional cell carcinoma

head and neck squamous cell carcinoma

lung small cell carcinoma

Therapies

Epacadostat + INCB001158

Epacadostat + INCB001158 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.